CA2999611A1 - Lrp5 as epigenetic marker for the identification of immune cells, in particular b-cells - Google Patents
Lrp5 as epigenetic marker for the identification of immune cells, in particular b-cells Download PDFInfo
- Publication number
- CA2999611A1 CA2999611A1 CA2999611A CA2999611A CA2999611A1 CA 2999611 A1 CA2999611 A1 CA 2999611A1 CA 2999611 A CA2999611 A CA 2999611A CA 2999611 A CA2999611 A CA 2999611A CA 2999611 A1 CA2999611 A1 CA 2999611A1
- Authority
- CA
- Canada
- Prior art keywords
- cells
- seq
- methylation
- cpg
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000001973 epigenetic effect Effects 0.000 title abstract description 8
- 210000002865 immune cell Anatomy 0.000 title abstract description 7
- 239000003550 marker Substances 0.000 title description 4
- 238000000034 method Methods 0.000 claims abstract description 67
- 210000003719 b-lymphocyte Anatomy 0.000 claims abstract description 58
- 210000004027 cell Anatomy 0.000 claims abstract description 39
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 31
- 230000011987 methylation Effects 0.000 claims abstract description 30
- 238000007069 methylation reaction Methods 0.000 claims abstract description 30
- 108010015167 Low Density Lipoprotein Receptor-Related Protein-5 Proteins 0.000 claims abstract description 21
- 102000001770 Low Density Lipoprotein Receptor-Related Protein-5 Human genes 0.000 claims abstract description 18
- 239000000523 sample Substances 0.000 claims abstract description 18
- 238000004458 analytical method Methods 0.000 claims abstract description 17
- 239000008280 blood Substances 0.000 claims abstract description 13
- 210000004369 blood Anatomy 0.000 claims abstract description 11
- 230000017858 demethylation Effects 0.000 claims abstract description 4
- 238000010520 demethylation reaction Methods 0.000 claims abstract description 4
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 claims description 31
- 108091093088 Amplicon Proteins 0.000 claims description 19
- 241000124008 Mammalia Species 0.000 claims description 16
- 108020004414 DNA Proteins 0.000 claims description 15
- 206010028980 Neoplasm Diseases 0.000 claims description 11
- 108091029523 CpG island Proteins 0.000 claims description 10
- 210000001519 tissue Anatomy 0.000 claims description 10
- 241000282414 Homo sapiens Species 0.000 claims description 9
- 201000011510 cancer Diseases 0.000 claims description 8
- 210000000822 natural killer cell Anatomy 0.000 claims description 8
- 238000012544 monitoring process Methods 0.000 claims description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
- 210000002443 helper t lymphocyte Anatomy 0.000 claims description 6
- 210000001616 monocyte Anatomy 0.000 claims description 6
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims description 5
- 210000003714 granulocyte Anatomy 0.000 claims description 5
- 210000000056 organ Anatomy 0.000 claims description 5
- 238000011002 quantification Methods 0.000 claims description 5
- 230000004044 response Effects 0.000 claims description 5
- 239000000126 substance Substances 0.000 claims description 5
- 238000001369 bisulfite sequencing Methods 0.000 claims description 4
- 208000023275 Autoimmune disease Diseases 0.000 claims description 3
- 108700039691 Genetic Promoter Regions Proteins 0.000 claims description 3
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 claims description 3
- 206010020751 Hypersensitivity Diseases 0.000 claims description 3
- 206010052779 Transplant rejections Diseases 0.000 claims description 3
- 208000026935 allergic disease Diseases 0.000 claims description 3
- 230000007815 allergy Effects 0.000 claims description 3
- 210000001124 body fluid Anatomy 0.000 claims description 3
- 239000010839 body fluid Substances 0.000 claims description 3
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 claims description 3
- 210000004698 lymphocyte Anatomy 0.000 claims description 3
- 108091026898 Leader sequence (mRNA) Proteins 0.000 claims description 2
- 108091036066 Three prime untranslated region Proteins 0.000 claims description 2
- 239000003153 chemical reaction reagent Substances 0.000 claims description 2
- 239000013068 control sample Substances 0.000 claims description 2
- 238000001514 detection method Methods 0.000 claims description 2
- 230000002255 enzymatic effect Effects 0.000 claims description 2
- 230000003325 follicular Effects 0.000 claims description 2
- -1 for example Proteins 0.000 claims description 2
- 208000015181 infectious disease Diseases 0.000 claims description 2
- 239000000463 material Substances 0.000 claims description 2
- 238000013518 transcription Methods 0.000 claims description 2
- 230000035897 transcription Effects 0.000 claims description 2
- 230000002103 transcriptional effect Effects 0.000 claims description 2
- 238000011144 upstream manufacturing Methods 0.000 claims description 2
- 239000012634 fragment Substances 0.000 claims 1
- 210000000601 blood cell Anatomy 0.000 abstract description 5
- 238000000338 in vitro Methods 0.000 abstract description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 29
- 102100021926 Low-density lipoprotein receptor-related protein 5 Human genes 0.000 description 13
- 229940104302 cytosine Drugs 0.000 description 13
- 230000004048 modification Effects 0.000 description 13
- 238000012986 modification Methods 0.000 description 13
- 230000007067 DNA methylation Effects 0.000 description 11
- 101001043594 Homo sapiens Low-density lipoprotein receptor-related protein 5 Proteins 0.000 description 11
- RYVNIFSIEDRLSJ-UHFFFAOYSA-N 5-(hydroxymethyl)cytosine Chemical compound NC=1NC(=O)N=CC=1CO RYVNIFSIEDRLSJ-UHFFFAOYSA-N 0.000 description 8
- 230000003321 amplification Effects 0.000 description 7
- 238000003199 nucleic acid amplification method Methods 0.000 description 7
- LRSASMSXMSNRBT-UHFFFAOYSA-N 5-methylcytosine Chemical compound CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 description 6
- 239000000090 biomarker Substances 0.000 description 5
- 210000000265 leukocyte Anatomy 0.000 description 5
- 210000001744 T-lymphocyte Anatomy 0.000 description 4
- BLQMCTXZEMGOJM-UHFFFAOYSA-N 5-carboxycytosine Chemical compound NC=1NC(=O)N=CC=1C(O)=O BLQMCTXZEMGOJM-UHFFFAOYSA-N 0.000 description 3
- FHSISDGOVSHJRW-UHFFFAOYSA-N 5-formylcytosine Chemical compound NC1=NC(=O)NC=C1C=O FHSISDGOVSHJRW-UHFFFAOYSA-N 0.000 description 3
- 208000030507 AIDS Diseases 0.000 description 3
- 230000008836 DNA modification Effects 0.000 description 3
- 108010033040 Histones Proteins 0.000 description 3
- 101100344028 Homo sapiens LRP5 gene Proteins 0.000 description 3
- 101150101996 LRP5 gene Proteins 0.000 description 3
- 238000011529 RT qPCR Methods 0.000 description 3
- 102000013814 Wnt Human genes 0.000 description 3
- 108050003627 Wnt Proteins 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 239000013256 coordination polymer Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 208000010543 22q11.2 deletion syndrome Diseases 0.000 description 2
- 206010003594 Ataxia telangiectasia Diseases 0.000 description 2
- 108091008875 B cell receptors Proteins 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 108091029430 CpG site Proteins 0.000 description 2
- 208000000398 DiGeorge Syndrome Diseases 0.000 description 2
- 208000031886 HIV Infections Diseases 0.000 description 2
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 2
- 102000006947 Histones Human genes 0.000 description 2
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 2
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 description 2
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 2
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 108700020796 Oncogene Proteins 0.000 description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 description 2
- 208000006110 Wiskott-Aldrich syndrome Diseases 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 210000000612 antigen-presenting cell Anatomy 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 101150008740 cpg-1 gene Proteins 0.000 description 2
- 230000004049 epigenetic modification Effects 0.000 description 2
- 230000006718 epigenetic regulation Effects 0.000 description 2
- 201000006417 multiple sclerosis Diseases 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- MJEQLGCFPLHMNV-UHFFFAOYSA-N 4-amino-1-(hydroxymethyl)pyrimidin-2-one Chemical compound NC=1C=CN(CO)C(=O)N=1 MJEQLGCFPLHMNV-UHFFFAOYSA-N 0.000 description 1
- 230000005730 ADP ribosylation Effects 0.000 description 1
- 206010001935 American trypanosomiasis Diseases 0.000 description 1
- 206010073478 Anaplastic large-cell lymphoma Diseases 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- 208000023328 Basedow disease Diseases 0.000 description 1
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 1
- 208000033222 Biliary cirrhosis primary Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 208000004918 Cartilage-hair hypoplasia Diseases 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 208000024699 Chagas disease Diseases 0.000 description 1
- 206010008609 Cholangitis sclerosing Diseases 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- 208000037088 Chromosome Breakage Diseases 0.000 description 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 206010010099 Combined immunodeficiency Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 238000000018 DNA microarray Methods 0.000 description 1
- 230000033616 DNA repair Effects 0.000 description 1
- 201000010046 Dilated cardiomyopathy Diseases 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 108010045438 Frizzled receptors Proteins 0.000 description 1
- 102000005698 Frizzled receptors Human genes 0.000 description 1
- 206010018372 Glomerulonephritis membranous Diseases 0.000 description 1
- 208000015023 Graves' disease Diseases 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000885581 Homo sapiens Frizzled-4 Proteins 0.000 description 1
- 101000990228 Homo sapiens Hemoglobin subunit mu Proteins 0.000 description 1
- 101000804764 Homo sapiens Lymphotactin Proteins 0.000 description 1
- 101000972806 Homo sapiens Protein naked cuticle homolog 1 Proteins 0.000 description 1
- 101000867413 Homo sapiens Segment polarity protein dishevelled homolog DVL-1 Proteins 0.000 description 1
- 208000010159 IgA glomerulonephritis Diseases 0.000 description 1
- 206010021263 IgA nephropathy Diseases 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 102000000853 LDL receptors Human genes 0.000 description 1
- 108010001831 LDL receptors Proteins 0.000 description 1
- 208000032004 Large-Cell Anaplastic Lymphoma Diseases 0.000 description 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
- 206010025327 Lymphopenia Diseases 0.000 description 1
- 102100035304 Lymphotactin Human genes 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 108010089610 Nuclear Proteins Proteins 0.000 description 1
- 102000007999 Nuclear Proteins Human genes 0.000 description 1
- 201000007142 Omenn syndrome Diseases 0.000 description 1
- 102000043276 Oncogene Human genes 0.000 description 1
- 208000007571 Ovarian Epithelial Carcinoma Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 206010034277 Pemphigoid Diseases 0.000 description 1
- 208000031845 Pernicious anaemia Diseases 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 208000012654 Primary biliary cholangitis Diseases 0.000 description 1
- 208000031951 Primary immunodeficiency Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 102100022560 Protein naked cuticle homolog 1 Human genes 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000239226 Scorpiones Species 0.000 description 1
- 206010054979 Secondary immunodeficiency Diseases 0.000 description 1
- 102100032758 Segment polarity protein dishevelled homolog DVL-1 Human genes 0.000 description 1
- 208000021386 Sjogren Syndrome Diseases 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 201000009594 Systemic Scleroderma Diseases 0.000 description 1
- 206010042953 Systemic sclerosis Diseases 0.000 description 1
- 201000001322 T cell deficiency Diseases 0.000 description 1
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 description 1
- 206010042971 T-cell lymphoma Diseases 0.000 description 1
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 206010047642 Vitiligo Diseases 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 238000001994 activation Methods 0.000 description 1
- 210000005006 adaptive immune system Anatomy 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 208000004631 alopecia areata Diseases 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 206010002449 angioimmunoblastic T-cell lymphoma Diseases 0.000 description 1
- 230000009831 antigen interaction Effects 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 201000008046 autosomal dominant osteopetrosis 1 Diseases 0.000 description 1
- 210000003651 basophil Anatomy 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 208000000594 bullous pemphigoid Diseases 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 208000006990 cholangiocarcinoma Diseases 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
- 230000006329 citrullination Effects 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 101150014604 cpg-3 gene Proteins 0.000 description 1
- 201000001981 dermatomyositis Diseases 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000007847 digital PCR Methods 0.000 description 1
- 201000011304 dilated cardiomyopathy 1A Diseases 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 210000001671 embryonic stem cell Anatomy 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 102000055426 human LRP5 Human genes 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 238000007031 hydroxymethylation reaction Methods 0.000 description 1
- 210000003297 immature b lymphocyte Anatomy 0.000 description 1
- 230000005965 immune activity Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000021121 meiosis Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 201000008350 membranous glomerulonephritis Diseases 0.000 description 1
- 231100000855 membranous nephropathy Toxicity 0.000 description 1
- 210000001806 memory b lymphocyte Anatomy 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 206010028417 myasthenia gravis Diseases 0.000 description 1
- 201000005962 mycosis fungoides Diseases 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 239000000101 novel biomarker Substances 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 201000001937 osteoporosis-pseudoglioma syndrome Diseases 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 210000004976 peripheral blood cell Anatomy 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 201000000742 primary sclerosing cholangitis Diseases 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000010837 receptor-mediated endocytosis Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000009711 regulatory function Effects 0.000 description 1
- 230000008672 reprogramming Effects 0.000 description 1
- 208000010157 sclerosing cholangitis Diseases 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 208000002491 severe combined immunodeficiency Diseases 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000021595 spermatogenesis Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000010741 sumoylation Effects 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 108091008023 transcriptional regulators Proteins 0.000 description 1
- 230000002463 transducing effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000034512 ubiquitination Effects 0.000 description 1
- 238000010798 ubiquitination Methods 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6881—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/154—Methylation markers
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Analytical Chemistry (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1516972.5A GB201516972D0 (en) | 2015-09-25 | 2015-09-25 | LRP5 as epigenetic marker for the identification of immune cells, in particular B-cells |
| GB1516972.5 | 2015-09-25 | ||
| PCT/EP2016/072579 WO2017050916A1 (en) | 2015-09-25 | 2016-09-22 | Lrp5 as epigenetic marker for the identification of immune cells, in particular b-cells |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2999611A1 true CA2999611A1 (en) | 2017-03-30 |
Family
ID=54544102
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2999611A Pending CA2999611A1 (en) | 2015-09-25 | 2016-09-22 | Lrp5 as epigenetic marker for the identification of immune cells, in particular b-cells |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US11643687B2 (enExample) |
| EP (1) | EP3353318B1 (enExample) |
| JP (1) | JP2018529345A (enExample) |
| CN (1) | CN108026578A (enExample) |
| CA (1) | CA2999611A1 (enExample) |
| GB (1) | GB201516972D0 (enExample) |
| HK (1) | HK1257122A1 (enExample) |
| WO (1) | WO2017050916A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019012543A1 (en) * | 2017-07-13 | 2019-01-17 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | DNA TARGETS AS SPECIFIC TISSUE METHYLATION MARKERS |
| JP2021518149A (ja) | 2018-03-26 | 2021-08-02 | オリジンセル セラピューティクス カンパニー リミテッド | 免疫細胞増殖を促進する方法 |
| DE102018112644B4 (de) * | 2018-05-25 | 2020-06-10 | Epiontis Gmbh | CXCR3 als epigenetischer Marker zur Identifizierung von inflammatorischen Immunzellen, insbesondere CD8+ Gedächnis-T-Zellen |
| DE102018116353B4 (de) | 2018-07-05 | 2020-06-10 | Epiontis Gmbh | Verfahren zum Nachweis und zur Zählung epigenetischer Immunzellen in humanen Blutproben für Immundiagnostik und Neugeborenen-Screening |
| DE102020108560B4 (de) * | 2020-03-27 | 2022-03-03 | Precision For Medicine Gmbh | CBX6 als epigenetischer Marker für die Identifizierung von Immunzellen, insbesondere Gedächtnis-B-Zellen |
| CN119372296B (zh) * | 2024-12-24 | 2025-06-13 | 北京致谱医学检验实验室有限公司 | 基于基因甲基化检测实现人b淋巴细胞计数的试剂盒 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2410253C (en) * | 2000-05-26 | 2010-06-15 | Genome Therapeutics Corporation | Regulating lipid levels via the zmax1 or hbm gene |
| DK1826279T3 (da) * | 2006-02-28 | 2011-09-05 | Charite Universitaetsmedizin | Detektering og kvalitetskontrol af regulatoriske t-celler vha. DNA-metyleringsanalyse af FoxP3--genet |
| CN101909630A (zh) * | 2007-11-02 | 2010-12-08 | 新加坡科技研究局 | 预防和治疗肿瘤的方法和化合物 |
| US20110104695A1 (en) * | 2009-11-05 | 2011-05-05 | Epigenomics Ag | Methods of predicting therapeutic efficacy of cancer therapy |
| US20130260378A1 (en) * | 2010-10-08 | 2013-10-03 | Epiontis Gmbh | Method for determining cancer patient survival based on analyzing tumorinfiltrating overall t-lymphocytes |
| WO2013033627A2 (en) | 2011-09-01 | 2013-03-07 | The Regents Of The University Of California | Diagnosis and treatment of arthritis using epigenetics |
| EP3561074B1 (en) * | 2013-04-19 | 2024-03-20 | Precision for Medicine GmbH | Method for identifying the quantitative cellular composition in a biological sample |
| BR112016028127A2 (pt) * | 2014-05-30 | 2017-08-22 | Philibert Robert | Status de metilação de dna como um biomarcador de uso e abstinência de álcool |
-
2015
- 2015-09-25 GB GBGB1516972.5A patent/GB201516972D0/en not_active Ceased
-
2016
- 2016-09-22 CA CA2999611A patent/CA2999611A1/en active Pending
- 2016-09-22 HK HK18116376.0A patent/HK1257122A1/zh unknown
- 2016-09-22 US US15/752,072 patent/US11643687B2/en active Active
- 2016-09-22 EP EP16770025.1A patent/EP3353318B1/en active Active
- 2016-09-22 CN CN201680052685.1A patent/CN108026578A/zh active Pending
- 2016-09-22 JP JP2018515528A patent/JP2018529345A/ja active Pending
- 2016-09-22 WO PCT/EP2016/072579 patent/WO2017050916A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| US20180216185A1 (en) | 2018-08-02 |
| GB201516972D0 (en) | 2015-11-11 |
| CN108026578A (zh) | 2018-05-11 |
| EP3353318A1 (en) | 2018-08-01 |
| US11643687B2 (en) | 2023-05-09 |
| JP2018529345A (ja) | 2018-10-11 |
| HK1257122A1 (zh) | 2019-10-11 |
| EP3353318B1 (en) | 2021-03-10 |
| WO2017050916A1 (en) | 2017-03-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11643687B2 (en) | LRP5 as epigenetic marker for the identification of immune cells, in particular B-cells | |
| EP3353319B1 (en) | Park2 as epigenetic marker for the identification of immune cells, in particular monocytes | |
| EP3353321B1 (en) | Mvd as epigenetic marker for the identification of cd56+ nk cells | |
| US11725243B2 (en) | Epigenetic method for the identification of follicular T-helper-(TFH-) cells | |
| US11680294B2 (en) | Amplicon region as epigenetic marker for the identification of non-classical monocytes | |
| CA3080060C (en) | Pdcd1 as epigenetic marker for the identification of immune cells, in particular pd1+ cells | |
| EP3669003B1 (en) | Pdcd1 as epigenetic marker for the identification of immune cells, in particular pd1+ cells | |
| AU2018356473A1 (en) | Endosialin (CD248) as epigenetic marker for the identification of immune cells, in particular naïve CD8+ T-cells | |
| CA3082261C (en) | Ergic1 as epigenetic marker for the identification of immune cells, in particular monocytic myeloid-derived suppressor cells (mmdscs) | |
| US11976327B2 (en) | ERGIC1 as epigenetic marker for the identification of immune cells, in particular monocytic myeloid-derived suppressor cells (mMDSCs) | |
| CA3101383A1 (en) | Cxcr3 as epigenetic marker for the identification of inflammatory immune cells, in particular cd8+ memory t cells | |
| HK1257582B (en) | Park2 as epigenetic marker for the identification of immune cells, in particular monocytes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20210818 |
|
| EEER | Examination request |
Effective date: 20210818 |
|
| EEER | Examination request |
Effective date: 20210818 |
|
| EEER | Examination request |
Effective date: 20210818 |
|
| EEER | Examination request |
Effective date: 20210818 |
|
| EEER | Examination request |
Effective date: 20210818 |
|
| EEER | Examination request |
Effective date: 20210818 |